RASolute-302 Data Signal a New Era for Pancreatic Cancer Drug Development

For much of the last decade, therapeutic progress in pancreatic cancer lagged far behind other KRAS-driven malignancies such as non–small cell lung cancer, where a series of targeted agents had already reached patients. Pancreatic cancer, despite being driven by KRAS mutations in the vast majority of cases, saw incremental survival gains from conventional chemotherapy regimens. That changed with the release of data from the phase 3 RASolute-302 trial (NCT06625320)at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which showed that the RAS(ON) multi-selective inhibitor daraxonrasib nearly doubled overall survival compared with standard of care in previously treated pancreatic cancer.

In an interview with CancerNetwork®, Frank McCormick, PhD, FRS, DSc (Hon), reflected on what that result meant for a field that had waited decades for a definitive proof of concept. McCormick, who has researched KRAS for 40 years and helped lead the National Cancer Institute’s RAS Initiative, explained that the RASolute-302 findings demonstrated there is nothing intrinsically untreatable about pancreatic cancer, only a longstanding need for a drug that could properly engage the correct molecular target. He described how the result reversed years of hesitancy among drug developers, transforming pancreatic cancer from a graveyard for failed trials into one of the most actively pursued indications in oncology drug development, with numerous additional KRAS-targeted agents now advancing through the pipeline behind daraxonrasib.

McCormick is a professor in the Helen Diller Family Comprehensive Cancer Center and holder of the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research at the University of California, San Francisco (UCSF).

Transcript:

That was obviously a wonderful moment for everybody in the field, and for patients and all those involved in treating pancreatic cancer. Up until that point, the progress made in targeting KRAS had really focused on lung cancer, where it’s also a major player, but there are already a lot of drugs that have been successful in lung cancer, targeting different proteins that cause the disease. To actually have a home run in pancreatic cancer was a real first, because nothing had been done up until that point. Apart from very incremental changes in survival benefit, there had been no impact really until those clinical data came out.

Suddenly, the whole field came to life in terms of realizing that targeting pancreatic cancer is really a question of getting the right drug and making it happen in the clinic. There’s nothing intrinsically impossible about pancreatic cancer; we just needed the right drug to target the right protein. Daraxonrasib will be the first of a lot of drugs being tested in pancreatic cancer right now, and we can expect them to get more and more potent, with fewer [adverse] effects, and to just improve the outcome of patients with pancreatic cancer by building on that result. Now it’s becoming so crowded in pancreatic cancer that it’s hard to get a foothold in the clinical research space, and that’s really a huge change. [Researchers] used to avoid trying drugs in pancreatic cancer because they never worked. Now it’s like a stampede of drugs coming into pancreatic cancer.